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1115-68 Predictors of Vascular Complications in Patients 
Undergoing Percutaneous Coronary Intervention and 
Treated With Vascular Closure Devices
Raj Goswami, John G. McGinnity, Arthur L. Riba, Cecelia K. Montoye, Dean E. Smith, 
Julius Gardin, Michael J. O'Donnell, Anthony C. DeFranco, David Share, Mauro 
Moscucci, For The Blue Cross Blue Shield of Michigan Cardiovascular Consortium 
(BMC2), University of Michigan, Ann Arbor, MI
Objective. The objective of our study was to identify clinical predictors of vascular com-
plications in patients undergoing contemporary percutaneous coronary interventions and
treated with vascular closure devices, VCDs (Vasoseal, Angioseal, Perclose, or others).
Methods. Clinical, procedural and outcome data on 27,202 consecutive PCIs were pro-
spectively collected between April 2001 and May 2003 in a consortium of 16 hospitals in
Michigan. Independent predictors of vascular complications (VC) were identified using
multivariate logistic regression analysis.
Results. 6270 patients received a vascular closure device. Vasoseal was used in 2.7%,
Angioseal in 41.9%, Perclose in 54.7% and other devices in 0.7%. The overall vascular
complication rate in this group was 3.3%. There was a non-significant trend toward an
increased incidence of VC in patients treated with Vasoseal (4.38%) when compared
with patients treated with Angioseal (2.98%) or Perclose (3.46%). Of 28 clinical and treat-
ment variables including type of vascular closure device, multivariate analysis identified
advanced age, female sex, acute myocardial infarction, cardiac arrest, cardiogenic shock
and glycoprotein IIb/IIIa receptor blocker use as independent predictors of VC (all
p<0.05).
Conclusions. Baseline clinical characteristics identify patients at increased risk of vas-
cular complications following use of VCD. The occurrence of vascular complications in
these patients appears to be independent of the type of VCD.
1115-69 Lower Hematocrit Is Associated With Worse Health 
Status in Patients With Heart Failure
Avinash Khanna, Mikhail Kosoborod, Philip Jones, Harlan M. Krumholz, John A. Spertus, 
Mid America Heart Institute and University of Missouri at Kansas City, Kansas City, MO, 
Yale University, New Haven, CT
Background: Anemia is a potentially modifiable comorbid condition in patients with heart
failure (HF). Its effect on health status has not been well defined. We tested the hypothe-
sis that lower hematocrit levels in patients with post-Myocardial Infarction (MI) HF are
associated with worse quality of life as measured by the Kansas City Cardiomyopathy
Questionnaire (KCCQ).
Methods: The EPHESUS trial enrolled 6632 patients with post-MI HF, of which 1578 par-
ticipated in the quality of life substudy. 3-month KCCQ scores were compared across the
following ranges of hematocrit: <0.33, 0.33-0.35, 0.36-0.38, 0.39-0.41, 0.42-0.44 and
>0.45. This time was selected to reflect a chronic HF state following patients’ MI.
Results: Compared with non-anemic patients, anemic patients (hematocrit <0.39) were
more likely to be female (46% vs 20%, p<0.001), older (68±24 vs 62±23, p<0.0001), dia-
betic (34% vs 23%, p<0.0001) and to have a higher serum creatinine (1.3 ± 1.0 vs 1.1±
0.6, p<0.001). Lower hematocrits were associated with worse (lower) KCCQ scores.
After adjusting for baseline demographic and clinical differences, a highly significant rela-
tionship between hematocrit and KCCQ summary scores was observed (Adjusted
Means shown in Figure, p<0.0001).
Conclusions: Lower hematocrits are associated with worse quality of life in HF patients,
even after controlling for a range of potentially confounding factors. Further investigation
of the health status benefits from correcting anemia in HF patients appears warranted. 
1115-70 Effect of Obesity on Long-Term Survival Following 
Percutaneous Coronary Intervention
Kenneth C. Wen, Timothy A. Sanborn, Warren Sherman, David L. Brown, Beth Israel 
Medical Center, New York, NY
Background: Obesity is a powerful risk factor for the development of coronary artery dis-
ease. Paradoxically, recent studies have suggested that obesity actually protects against
mortality following percutaneous coronary intervention (PCI).We sought to determine the
impact of obesity on long-term survival following PCI using a contemporary database.
Methods: The study population consisted of 4284 consecutive patients undergoing PCI
from January 1, 1998 to October 1, 1999 at 3 hospitals in New York City. Patients were
then divided into two groups, obese patients with body mass index (BMI) > 30 (n=1,410)
and non-obese patients with BMI < 30 (n=2,874). Primary endpoint was all-cause mortal-
ity following the index PCI. Mean follow-up was 3 years. Results: Obese patients were
younger (60 vs. 65 years, P<0.001) and more frequently female (36% vs. 29%, P<0.001).
Mean BMI was 34.7 in the obese patients and 25.6 in the non-obese patients (P<0.001).
Hypertension (74% vs. 68%, P<0.001) and diabetes (33% vs. 24%, P<0.001) were more
common in obese patients while peripheral vascular disease (6.1% vs. 8.7%, P<0.001)
and prior bypass surgery (14% vs. 19%, P<0.001) were less common. Presentation with
myocardial infarction (9.4% vs. 11%, P=NS) and unstable angina (41% vs. 43%, P=NS)
did not differ between obese and non-obese patients. Single-vessel coronary disease
was more common in obese patients (53% vs. 46%, P<0.001) and mean ejection frac-
tions were slightly greater (51% vs. 50%, P=0.04). Stent use did not differ between
groups. Angiographic success was slightly reduced in obese patients (96% vs. 97%,
P=0.06). In-hospital major adverse cardiac events did not differ between obese and non-
obese patients. Out-of-hospital death was 7.2% for obese patients and 10.3% in the non-
obese (P=0.001). After adjustment for differences in baseline characteristics, obesity was
found not to be associated with an increased hazard of long-term mortality (Hazard
Ratio, 0.992, 95% Confidence Interval, 0.784 – 1.254, P=0.945). Conclusion: Obesity
does not appear to protect patients from long-term mortality following PCI. However, nei-
ther does it increase the hazard of 3-year mortality after adjustment for other co-morbidi-
ties.
1115-71 Depression Is Strongly Associated With Worse Health 
Status in Patients With Myocardial Infarction 
Complicated by Heart Failure: Data From the EPHESUS 
Trial
John S. Rumsfeld, Mary A. Whooley, Philip Jones, Mark D. Sullivan, Pamela N. Peterson, 
William S. Weintraub, Bertram Pitt, John A. Spertus, Denver VA Medical Center, Denver, 
CO, University of Missouri-Kansas City, Kansas City, MO
Background: We evaluated the relationship between depression and health status in
patients with acute MI complicated by heart failure.
Methods: Patients in the EPHESUS trail (NEJM, 2003) completed a Medical Outcomes
Study-Depression (MOS-D) questionnaire at baseline and Kansas City Cardiomyopathy
Questionnaire (KCCQ) at baseline,1,3,6, and 12 months. The KCCQ measures heart-
failure health status including symptoms, physical function, and quality of life. The KCCQ
summary score has range 0-100; higher scores = better health status; 5 points = clini-
cally important score difference. We used repeated measures and multivariable regres-
sion to evaluate the association between depressive symptoms (MOS-D score > 0.06)
and KCCQ summary scores.
Results: 93/423 patients (22%) had significant depressive symptoms. Depressed
patients had markedly lower KCCQ scores during follow-up (Figure). After risk adjust-
ment, depression remained significantly associated with worse baseline (p<0.001) and
12-month (p<0.001) KCCQ scores - on average, depressed patients had 8.8 point lower
KCCQ scores at baseline and 13.4 point lower KCCQ scores at 12-months. Depressive
symptoms were the strongest predictor of health status in the multivariable models.
Conclusion: In patients with AMI complicated by heart failure, depressive symptoms are
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Treatment Angioplasty Clinica
l
Surgery p
Period pre 12m 24m pre 12m 24m pre 12m 24m
Physical Functioning 59 72,8 72,44 50 66,2 62,50 47 73,5 73,69 0,002
Role Physical 34 52,6 51,13 23 39,8 38,49 21 48,2 50,19 0,018
General Health 65 63,8 66,09 63 60,8 62,40 63 64,4 68,19 0,018
Mental Health 66 74,6 42,59 63 70,4 42,47 64 74 41,14 NS
Vitality 64 72,2 46,13 56 61,6 41,94 56 73,8 45,27 0,02
Role Emotional 52 67,1 69,92 50 64,9 64,91 46 68,9 68,72 NS
Social Functioning 58 70 86,28 57 62,7 80,35 53 66,9 87,60 0,02
Bodly Pain 63 75,4 70,50 62 70,1 67,30 57 76,8 73,55 NS
